home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410m.zip
/
M94A2287.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
49 lines
Document 2287
DOCN M94A2287
TI Acceptability of HIV vaccine trials in high risk cohorts in Mombasa,
Kenya.
DT 9412
AU Bwayo J; Jackson D; Rakwar J; Nyange P; Martin H; Kreiss J; Department
of Medical Microbiology, University of Nairobi, Kenya.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):339 (abstract no. PC0291). Unique
Identifier : AIDSLINE ICA10/94370288
AB OBJECTIVE: To assess the acceptability of phase III trials of candidate
HIV vaccines in high risk male and female prospective cohorts in
Mombasa. METHODS: A standardised questionnaire was administered to a
sample of HIV seronegative male (m) trucking company employees (n = 67)
and female (f) sex workers (n = 61) who were enrolled in existing HIV
high risk cohort studies, as part of the Preparation for AIDS Vaccine
Evaluation initiative. RESULTS: General knowledge about vaccines was
tested, with 78% (75%f, 81%m) giving a correct definition of a vaccine,
91% (88%f, 93%m) able to name a vaccine preventable disease, 48% (48%f,
49%m) knowing that vaccines are not 100% efficacious, and 34% (33%f,
36%m) aware that vaccines could have side effects. While 93% (90%f,
96%m) thought that HIV was a major problem in Kenya, 12% (15%f, 9%m)
felt at no personal risk of HIV infection. If offered a safe,
efficacious HIV vaccine, 89% (89%f, 90%m) stated that they would accept.
If offered participation in a randomized trial of a candidate HIV
vaccine of unknown efficacy, 84% (87%f, 81%m) agreed to a double blind
placebo controlled design, 80% (77%f, 82%m) agreed to participate even
if the vaccine gave them a false positive HIV serologic result, and 84%
(87%f, 81%m) agreed to a follow up period of 3 to 5 years. Two
respondants (1f, 1m) said they would increase their number of sex
partners if in a vaccine trial and 12% (3%f, 19%m) stated that they
would decrease condom use. This gender difference in anticipated change
in condom use was the only such difference which was statistically
significant (p = 0.01). At the end of the questionnaire, 84% (85%f,
82%m) said they would participate in an HIV vaccine trial, as outlined.
DISCUSSION: These results suggest that acceptance of an HIV vaccine
trial would be high in these cohorts. That 19% of men stated that they
would decrease condom use if in an HIV vaccine trial highlights the need
for continuing education.
DE Adult Clinical Trials, Phase III/*STATISTICS & NUMER DATA Cohort
Studies Condoms *Developing Countries Feasibility Studies Female
Human HIV Infections/EPIDEMIOLOGY/*PREVENTION & CONTROL/TRANSMISSION
Kenya/EPIDEMIOLOGY Knowledge, Attitudes, Practice Male *Patient
Acceptance of Health Care Prospective Studies Risk Factors MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).